BioAtla, Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BioAtla, Inc. | ||
| Date: March 31, 2026 | By: | /s/ Jay M. Short, Ph.D. |
|---|---|---|
| Jay M. Short, Ph.D. | ||
| Chief Executive Officer(Principal Executive Officer and Authorized Signatory) | ||
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jay M. Short, Ph.D. and Christian Vasquez as his or her true and lawful attorneys-in-fact, and each of them, with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, and either of them, or his or their substitute or substitutes may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| SIGNATURE | TITLE | DATE |
|---|---|---|
| /s/ Jay M. Short, Ph.D.Jay M. Short, Ph.D. | Chief Executive Officer and Director(Principal Executive Officer) | March 31, 2026 |
| /s/ Christian VasquezChristian Vasquez | Chief Financial Officer(Principal Financial and Accounting Officer) | March 31, 2026 |
| /s/ Scott SmithScott Smith | Director | March 31, 2026 |
| /s/ Lawrence Steinman, M.D.Lawrence Steinman, M.D. | Director | March 31, 2026 |
| /s/ Mary Ann Gray, Ph.D.Mary Ann Gray, Ph.D. | Director | March 31, 2026 |
| /s/ Susan Moran, M.D.Susan Moran, M.D. | Director | March 31, 2026 |
| /s/ Sylvia McBrinnSylvia McBrinn | Director | March 31, 2026 |
| /s/ Edward Williams | Director | March 31, 2026 |
| Edward Williams | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.